-
The seventh batch of national procurement is connected to MAH, and the threshold for domestic agents is raised, which is beneficial to enterprises with their own production lines
Time of Update: 2022-08-15
0 1 The threshold for domestic agents is raised In terms of application qualifications, the seventh batch of centralized procurement requires domestic drug manufacturers, drug marketing authorization holders, and domestic agents of overseas drug marketing authorization holders that provide drugs and accompanying services, in terms of quality standards, production capacity, supply stability, Those who meet the requirements of this centralized procurement in terms of corporate credit and other aspects can participate .
-
Listed pharmaceutical companies get together to become LPs become the norm!
Time of Update: 2022-08-15
, Ltd. and another company with 50% of their respective contributions, and manages a fund, namely the Liaoning Sunshine Medical Industry Investment Fund Partnership (Limited Partnership) established in 2017 .
-
Notice on the adjustment of the exhibition period of the 88th API China and the 26th CHINA-PHARM
Time of Update: 2022-08-15
Dear exhibitors, visitors and friends in the industry: In view of the recent spread of the epidemic in many places in China, the prevention and control situation is still severe and complicated. A pr
-
XRF/Solid Waste Analysis Standards/Hazardous Elements Determination Sharing is collected!
Time of Update: 2022-08-15
[Pharmaceutical Network Conference Forum] At 14:00 on June 23, 2022, a webinar on elemental analysis of solid waste and hazardous waste has been presented on the environmental protection online HB li
-
Oseltamivir won the bid for the seventh batch of centralized procurement at 0.99 yuan per pill, and the "one product is the only one" is under pressure!
Time of Update: 2022-08-15
Both multinational and local companies must face the premium criteria for innovative products in the medical insurance payment market The industry generally believes that the centralized procurement of drugs with a large amount has brought about a fundamental change in the pharmaceutical industry.
-
The highest drop is 97%!
Time of Update: 2022-08-15
, the quotation strategy is becoming more and more mature The average price of the drugs to be selected is reduced by 48%; it is the same as the special centralized procurement of insulin, but the decline is moderated compared with the first five batches of centralized procurement.
-
Domestic pharmaceutical companies are accelerating their entry into the diabetes drug market!
Time of Update: 2022-08-15
Sugar drugs have been approved for marketing one after another At present, driven by multiple factors such as the continuous growth of diabetes patients in China, the successive entry of new diabetes treatment drugs into the medical insurance catalog, and the enhancement of patients' ability to pay, more and more domestic companies have begun to accelerate their deployment in this field.
-
Heavy!
Time of Update: 2022-08-15
com Tel: 18001678807 (Shanghai Food and Drug Packaging Materials Testing Institute); 010﹣67079620 (State Pharmacopoeia Commission) Feedback on the Draft General Test Method for Rubber Seals for Pharmaceutical Packaging Can be sent to: jiangyan@scsyjs.
-
BMS Announces Latest Data on Lung Cancer with Immune Combination Therapy Opdivo+Yervoy
Time of Update: 2022-08-15
. 5-year follow-up results from the first part of the phase 3 CheckMate-227 trial showed a long-term, durable survival benefit with Opdivo+Yervoy as first-line therapy compared with chemotherapy in previously untreated patients with mNSCLC, regardless of PD-L1 expression How is the level .
-
The results of the seventh batch of centralized collection are released, how did Qilu "kill the madness"?
Time of Update: 2022-08-15
The King of Consistency Evaluation: Qilu's review performance As of July 12, 2022, Qilu Pharmaceutical Group has accumulatively reviewed (including deemed approved) 112 drug varieties, and has accumulated 193 approvals (see the end of the article for details), making it a leader among major companies .
-
The 2028 global pharmaceutical giant TOP10 prediction list is released, and the rankings are reshuffled!
Time of Update: 2022-08-15
Big pharma rankings reshuffle Roche's sales ranking is expected to rise from the current fifth position to second, as its multiple sclerosis drug Ocrevus (ocrelizumab), anti-PD-L1 immunotherapy Tecentriq (atezolizumab) and The hemophilia drug Shuyouli/Hemlibra (emerizumab) is expected to grow strongly over the next six years .
-
Since 2022, single pharmacy franchise chain enterprises are receiving strong support!
Time of Update: 2022-08-15
. According to Yifeng’s financial report, according to the development strategy of “regional focus and steady expansion”, the company will add 297 franchised stores in 2021 through the store expansion model of “newly opened mergers and acquisitions”, a year-on-year increase of 19.
-
Hengrui's 10 new drugs were approved, refreshing market investment expectations!
Time of Update: 2022-08-15
?Since the beginning of this year, the capital market has reassessed the value of China's pharmaceutical innovation, and the stock prices of a large number of pharmaceutical innovation companies represented by Hengrui Medicine have fallen .
-
Guangdong's biopharmaceutical industry is full of innovative vitality!
Time of Update: 2022-08-15
In recent years, with the support of a series of favorable policies for the research and development of innovative traditional Chinese medicines, both the number of applications and the number of approvals have increased significantly .
-
In the new clinical era, how to follow the blinding principle of clinical trials?
Time of Update: 2022-08-15
Emergency unblinding refers to obtaining information on the treatment grouping of a single or part of subjects in emergency situations through pre-established standard operating procedures based on subject safety considerations and other special reasons in accordance with the provisions of the clinical trial protocol .
-
A unified national medical insurance information platform covering 1.36 billion insured persons has been fully established
Time of Update: 2022-08-15
According to the latest news from the National Medical Insurance Administration, a unified national medical insurance information platform has been fully established, and it has been launched in 31 p
-
The transformation ideas and databases are ready. Are you the green and low-carbon coordinated development forum?
Time of Update: 2022-08-15
(Click the image above / scan the QR code to review) The topic of green and low carbon is frequently searched, and the transformation under the "two-carbon" goal is irreversible [Pharmaceutical Network Conference Forum] Have an appointment every Monday, such a "hard-working" expert lecture hall of the 2022 Qingdao International Water Conference, have you?
-
With the continuous improvement of innovation capabilities of local pharmaceutical companies, they are accelerating their internationalization strategies
Time of Update: 2022-08-15
Recently, it was reported that the international multi-center phase III clinical trial of 2 innovative drugs of Hengrui Medicine of camrelizumab for injection (Erica®) combined with apatinib mesylate tablets (Aitan®) (SHR-1210-III-310) The independent data monitoring committee (IDMC) judged that the primary endpoint of the study met the protocol-preset superiority standard .
-
Pharmaceutical companies are competing for the beauty track, and pharmacies are also accelerating their entry
Time of Update: 2022-08-15
. It is worth noting that, in addition to pharmaceutical companies, some leading chain pharmacies have also begun to boldly promote the process of cosmeceutical franchises and deploy cosmeceuticals under the background of large-scale procurement and medical insurance control fees that have greatly squeezed the profits of the pharmaceutical retail industry.
-
Seeing "her power": within one day, many pharmaceutical companies announced new female executives!
Time of Update: 2022-08-15
Among them, on July 28, the company announced that its board of directors received written resignation reports from director and general manager Wang Hongxin and deputy general managers Yuan Yingsheng and Chen Jing According to the company's previous announcement, the senior executives of China Pharmaceutical changed frequently during the year.
